Everything on Pharmaceutical Strategy & Capital Allocation

Sanofi’s heavy reliance on Dupixent (~30% of revenue) with a 2031 patent expiry creates concentration risk, partially offset by a ~5% dividend yield and active pipeline development.

Impact: Balancing high dividend payouts with R&D investment requires careful monitoring of clinical trial outcomes and M&A activity to ensure post-patent-cliff sustainability.

— from Corporate Pivots, Cloud Margins, and Infrastructure Booms · Aktien fürs Leben· Apr 29, 2026